Novo Nordisk and Eli Lilly announce “Made in France” – Libération

Danish and American sector leaders are thriving in the stock market. Although not sold in France, their drugs will soon be produced there thanks to significant investment.

Soon Ozempic, Wegovy and even Zepbound will be “made in France”… although these anti-obesity products are not yet sold in France. At the end of November 2023, Danish giant Novo Nordisk invested more than 2 billion euros in its plant in Chartres, which produces these diabetes and obesity drugs. After visiting the site, Emmanuel Macron welcomed the investment “unprecedented in the French pharmaceutical industry.” More than 500 new jobs will be created in addition to the existing 1,600 employees, and production capacity will be doubled by expanding the site to 230,000 m² by 2028.

Since 2010, Novo Nordisk has already invested more than 450 million euros in France, including 130 million at the beginning of 2023 in new assembly and packaging lines. Its Chartres facility mainly produces injector pens intended for diabetic patients. M